Hayden is an assistant editor for The American Journal of Managed Care® (AJMC®) and joined AJMC® in 2021, where she produces written and video content covering multiple disease states.
She has a BA in journalism & media studies from Rutgers University. You can connect with Hayden on LinkedIn.
Dr Jeremy Abramson Discusses CAR T-Cell Therapy Timing in DLBCL
February 4th 2023Jeremy Abramson, MD, director of the Jon and Jo Ann Hagler Center for Lymphoma at the Massachusetts General Hospital Cancer Center, shared his take on the potential benefits of chimeric antigen receptor (CAR) T-cell therapy in earlier lines of treatment.
Read More
Adults With Diabetes in High-Deductible Health Plans More Likely to Have Severe Hyperglycemia
January 26th 2023Adults with diabetes who were forced to switch from an employer-sponsored health plan to a high-deductible health plan (HDHP) were 25% more likely to require an emergency department (ED) or hospital visit for hyperglycemia, but not for hypoglycemia, than those who did not switch plans.
Read More
Fetal Outcomes, Maternal Mortality Vary Among Pregnant Women With Different Types of PH
January 19th 2023A small study conducted in China suggests pregnant women with idiopathic pulmonary arterial hypertension (iPAH) are at higher risk of maternal mortality compared with women with certain other types of pulmonary hypertension (PH).
Read More
Social Determinants of Health Linked With Varying Prostate Cancer Outcomes by Race
January 13th 2023A meta-analysis supported that Black men have similar or better prostate cancer outcomes compared with White men when health care access is equal and treatment is standardized for all patients.
Read More
In Pediatric Epilepsy, Links Found Between Parental Factors, Emotional and Behavioral Issues
January 10th 2023A study showed 18.3% of adolescents with epilepsy (AWE) had at least 1 emotional or behavioral problem, and 24.9% of parents felt others had stigma towards their children with epilepsy.
Read More
Age Considerations for Findings on Venetoclax Combined With CLIA for AML, High-Risk MDS
December 29th 2022Patrick Reville, MD, MPH, instructor, Department of Leukemia, MD Anderson Cancer Center, explains the implications of the longer-term follow-up of venetoclax in combination with the chemotherapy regimen cladribine, high-dose cytarabine, idarubicin (CLIA) and how age is a factor when considering chemotherapy options.
Read More
Dr Davey Daniel Talks Approval of Cemiplimab With Chemotherapy for First-line NSCLC
December 21st 2022Cemiplimab with chemotherapy appears to offer value comparable to other options and may be "an important tool to use" in first-line treatment of non-small cell lung cancer (NSCLC), said Davey Daniel, MD, chief medical officer for OneOncology, lung cancer specialist.
Read More